SCI Abstract

search
+
Biomarkers and treatment updates in renal cell carcinoma
Biomarkers and treatment updates in renal cell carcinoma
At this year’s ASCO Annual Meeting, researchers presented detailed findings concerning biomarkers and rare subtypes ...
ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer
ASCO highlights: neoadjuvant immunotherapy in mismatch repair deficient colorectal cancer
Despite recent advances in therapy, certain subtypes of colorectal cancer, such as those that are microsatellite instabili...
Diffuse large B-cell lymphoma of the right upper extremity misdiagnosed as soft tissue infection
Diffuse large B-cell lymphoma of the right upper extremity misdiagnosed as soft tissue infection
Diffuse large B‑cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma (NHL). It can originate in ...
Prognostic tools and risk factors in early-stage CLL—time for a change in treatment paradigm?
Prognostic tools and risk factors in early-stage CLL—time for a change in treatment paradigm?
Chronic lymphocytic leukemia (CLL) is one of the most common lymphoid malignancies. Due to its biological heterogeneity, t...
Evaluating antifungal prophylaxis strategies in pediatric acute myeloid leukemia: a retrospective, single-center analysis of amphotericin B, itraconazole, and voriconazole
Evaluating antifungal prophylaxis strategies in pediatric acute myeloid leukemia: a retrospective, single-center analysis of amphotericin B, itraconazole, and voriconazole
Invasive fungal disease (IFD) represents a major cause of morbidity and mortality in pediatric patients with acut...
Cure for multiple myeloma?
Cure for multiple myeloma?
Advances in our knowledge of the pathogenesis of multiple myeloma and the resultant development of novel therapies have si...
EffiXane—Non-interventional study on safety and effectiveness of -paclitaxel (Abraxane®) + gemcitabine as first-line treatment of metastatic PDAC in a daily routine setting
EffiXane—Non-interventional study on safety and effectiveness of -paclitaxel (Abraxane®) + gemcitabine as first-line treatment of metastatic PDAC in a daily routine setting
Metastatic adenocarcinoma of the pancreas (PDAC) was one of the most common causes of cancer-associated death in Europe an...
Too frail or not too frail? Prognosis and treatment options in older CLL patients
Too frail or not too frail? Prognosis and treatment options in older CLL patients
Chronic lymphocytic leukemia (CLL) is a disease that primarily affects older patients, with a median age...
A short review on the current status of PSMA ligands used for PSMA-PET/CT imaging
A short review on the current status of PSMA ligands used for PSMA-PET/CT imaging
In recent years, prostate-specific membrane antigen (PSMA)-targeted positron emission tomography/computed tomography (PET/...
American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia
American Society of Hematology (ASH) update 2023—chronic lymphocytic leukemia
In recent years, there has been massive advances in the treatment of chronic lymphocytic leukemia (CLL) from chemoimmunoth...
Unclassifiable acute leukemia with blastic plasmacytoid dendritic cell neoplasm: deciding on the appropriate therapy
Unclassifiable acute leukemia with blastic plasmacytoid dendritic cell neoplasm: deciding on the appropriate therapy
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare, clinically aggressive tumor derived from the precursors of...
BACE (Bendamustine, Cytarabine, Cyclophosphamide and Etoposide) conditioning regime for patients with lymphoma undergoing autologous stem cell transplant
BACE (Bendamustine, Cytarabine, Cyclophosphamide and Etoposide) conditioning regime for patients with lymphoma undergoing autologous stem cell transplant
Autologous stem cell transplant (ASCT) is a curative treatment for lymphomas. BEAM conditioning (Carmustine, Etoposide, Cy...
Implantable catheter chambers: a 14-year descriptive study
Implantable catheter chambers: a 14-year descriptive study
Implantable catheter chambers are widely used devices during the treatment of cancer whether for taking blood samples or f...
State-of-the-art therapy and innovative treatment strategies in esophageal squamous cell cancer
State-of-the-art therapy and innovative treatment strategies in esophageal squamous cell cancer
Recent advances in the development of new therapeutic agents and the execution of numerous randomized controlled trials ha...
Impact of the WHO-5 classification of haematolymphoid tumours on clinical practice
Impact of the WHO-5 classification of haematolymphoid tumours on clinical practice
The long-awaited 2022 World Health Organization Classification of Haematolymphoid Tumours (WHO-5-HAEM) has finally been pu...
Pulmonary puzzles: salivary gland-type tumors of the lung and their metastatic equivalents
Pulmonary puzzles: salivary gland-type tumors of the lung and their metastatic equivalents
In the last decade, the understanding of lung neoplasms, particularly rare salivary gland-type tumors (SGT), has deepened ...
Liquid profiling for patients with advanced cancer is ready for clinical integration
Liquid profiling for patients with advanced cancer is ready for clinical integration
Molecular profiling of circulating tumor DNA (ctDNA) to guide treatment decisions has found its way into routine managemen...
GATA2 deficiency: a mystery myelodysplasia
GATA2 deficiency: a mystery myelodysplasia
GATA2 deficiency, arising from mutations in the GATA2 gene, is a rare genetic disorder with profound implications...
Novel mutated Dubin–Johnson syndrome diagnosed during acute promyelocytic leukemia treatment
Novel mutated Dubin–Johnson syndrome diagnosed during acute promyelocytic leukemia treatment
Coexistence of acute promyelocytic leukemia and Dubin–Johnson syndrome (DJS) has not been previously reported in the...
Importance of allogeneic stem cell transplantation in myelofibrosis
Importance of allogeneic stem cell transplantation in myelofibrosis
Allogeneic stem cell transplantation (alloSCT) is the only curative treatment option for patients with high-risk myelofibr...
KRAS (Kirsten rat sarcoma) in modern oncology—The molecular pathological point of view
KRAS (Kirsten rat sarcoma) in modern oncology—The molecular pathological point of view
The Rat sarcoma protein (RAS) was the first proto-oncogene to be discovered and is one of the best researched tumor driver...
ASCO 2023: highlights in breast cancer
ASCO 2023: highlights in breast cancer
The 2023 annual meeting of the American Society of Clinical Oncology (ASCO) was again held in June 2023 in Chicag...
Cancer of unknown primary—state of the art
Cancer of unknown primary—state of the art
The Cancer of Unknown Primary (CUP) syndrome does not represent a single clinical entity but comprises a diverse group of ...
Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023
Emerging treatment strategies in chronic B-cell malignancies—News from ICML 2023
Implementation of targeted drugs in the treatment landscape of indolent B‑cell malignancies has facilitated long-ter...
Supportive management
Supportive management
The introduction of checkpoint inhibitor therapy and advances in targeted therapy...
Prostate cancer special—part 1
Prostate cancer special—part 1
Conflict of interest S.F. Shariat declares the following competing interes...
HER2 in focus—gastric cancer
HER2 in focus—gastric cancer
Conflict of interest A. Ilhan-Mutlu: Participation in advisory boards orga...
ASCO 2023—partnering with patients: the cornerstone of cancer care and research
ASCO 2023—partnering with patients: the cornerstone of cancer care and research
For the 2023 annual meeting of the American Society of Clinical Oncology (ASC...
WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients
WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients
The Wnt pathway is aberrantly activated in chronic lymphocytic leukemia (CLL) and contributes to the antiapoptotic and mit...
A CONGRESS DIGEST ON RADIOLABELED THERANOSTICS FOR SOLID TUMORS. Report from the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), September 9th – 13th, 2023, Vienna
A CONGRESS DIGEST ON RADIOLABELED THERANOSTICS FOR SOLID TUMORS. Report from the 36th Annual Congress of the European Association of Nuclear Medicine (EANM), September 9th – 13th, 2023, Vienna
Share this articleAnyone you share the following link with will be able to read this content:Get shareable linkSorry, a sh...
Load More
format_indent_increase